Parathyroid hormone
- Generic Name
- Parathyroid hormone
- Brand Names
- Natpara, Natpar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9002-64-6
- Unique Ingredient Identifier
- N19A0T0E5J
- Background
Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide...
- Indication
For use/treatment in osteoporosis.
- Associated Conditions
- Hypocalcemia, Hypoparathyroidism
- Associated Therapies
- -
A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 96
- Registration Number
- NCT05137730
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Shire
- Registration Number
- NCT03878953
- Locations
- ๐ฏ๐ต
Osaka City University Hospital, Osaka-shi, Osaka-Fu, Japan
๐ฏ๐ตShimane University Hospital, Izumo-shi, Shimane-Ken, Japan
๐ฏ๐ตUniversity of Tokyo Hospital, Bunkyo-ku, Tokyo-To, Japan
Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Shire
- Target Recruit Count
- 24
- Registration Number
- NCT03150108
- Locations
- ๐บ๐ธ
Glendale Adventist Medical Center, Glendale, California, United States
A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Shire
- Target Recruit Count
- 39
- Registration Number
- NCT02910466
- Locations
- ๐บ๐ธ
Columbia University Medical Center, New York, New York, United States
Treatment With PTH After Sternotomy in Cardiac Surgery Patients
- Conditions
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 20
- Registration Number
- NCT01466829
- Locations
- ๐ฉ๐ฐ
Dept. of Cardiothoracic & Vascular Surgery, AArhus University Hospital, Skejby, Aarhus N, Denmark
PTH & Ibandronate Combination Study (PICS)
- Conditions
- Interventions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 44
- Registration Number
- NCT00683163
- Locations
- ๐บ๐ธ
University of California, San Francisco, San Francisco, California, United States
Bone Properties in Hypoparathyroidism: Effects of PTH
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- John P. Bilezikian
- Target Recruit Count
- 68
- Registration Number
- NCT00473265
- Locations
- ๐บ๐ธ
Columbia University, New York, New York, United States
Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 60
- Registration Number
- NCT00221299
- Locations
- ๐บ๐ธ
UC Davis General Medicine Research Clinic, Sacramento, California, United States
rhPTH Therapy for Low Turnover Bone Fragility
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT00145886
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
- First Posted Date
- 2000-03-27
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- Dennis Black
- Target Recruit Count
- 238
- Registration Number
- NCT00005005
- Locations
- ๐บ๐ธ
University of Minnesota, Minneapolis, Minnesota, United States
๐บ๐ธUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธMaine Center for Osteoporosis, Bangor, Maine, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.